GeneDx Holdings Corp. (WGS) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $61.19 (-0.38%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 24, 2026 | Mark Massaro | BTIG | $170.00 | +177.8% |
| Feb 24, 2026 | David Westenberg | Piper Sandler | $130.00 | +112.5% |
| Oct 24, 2024 | Bill Bonello | Craig-Hallum | $70.00 | +14.4% |
| Aug 27, 2024 | Brandon Couillard | Wells Fargo | $34.00 | -44.4% |
| Jul 31, 2024 | Mark Massaro | BTIG | $45.00 | -26.5% |
| Jul 10, 2024 | Bill Bonello | Craig-Hallum | $43.00 | -29.7% |
| Jun 26, 2024 | Mark Massaro | BTIG | $35.00 | -42.8% |
| Jun 3, 2024 | Tycho Peterson | Jefferies | $21.00 | -65.7% |
| Apr 30, 2024 | Mark Massaro | BTIG | $19.00 | -68.9% |
Top Analysts Covering WGS
WGS vs Sector & Market
| Metric | WGS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 10 | 8 | 19 |
| Target Upside | +59.5% | +11475.0% | +17.1% |
| P/E Ratio | -84.52 | 3.99 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $539M | $550M | $560M | 6 |
| 2027-03-31 | $147M | $148M | $151M | 2 |
| 2027-06-30 | $164M | $165M | $167M | 2 |
| 2027-09-30 | $179M | $181M | $183M | 2 |
| 2027-12-31 | $192M | $193M | $196M | 2 |
| 2028-03-31 | $169M | $170M | $172M | 1 |
| 2028-06-30 | $195M | $197M | $200M | 1 |
| 2028-09-30 | $221M | $222M | $226M | 1 |
| 2028-12-31 | $243M | $245M | $248M | 1 |
| 2029-12-31 | $1.02B | $1.04B | $1.06B | 2 |
| 2030-12-31 | $1.33B | $1.36B | $1.38B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.77 | $0.79 | $0.81 | 3 |
| 2027-03-31 | $0.30 | $0.31 | $0.31 | 2 |
| 2027-06-30 | $0.43 | $0.44 | $0.45 | 1 |
| 2027-09-30 | $0.55 | $0.56 | $0.57 | 1 |
| 2027-12-31 | $0.56 | $0.57 | $0.58 | 2 |
| 2028-03-31 | $0.10 | $0.10 | $0.11 | 3 |
| 2028-06-30 | $0.43 | $0.43 | $0.44 | 2 |
| 2028-09-30 | $0.71 | $0.72 | $0.73 | 2 |
| 2028-12-31 | $0.81 | $0.81 | $0.83 | 3 |
| 2029-12-31 | $4.97 | $5.11 | $5.22 | 1 |
| 2030-12-31 | $7.93 | $8.14 | $8.33 | 1 |
Frequently Asked Questions
What is the analyst consensus for WGS?
The consensus among 10 analysts covering GeneDx Holdings Corp. (WGS) is Buy with an average price target of $141.00.
What is the highest price target for WGS?
The highest price target for WGS is $170.00, set by Mark Massaro at BTIG on 2026-02-24.
What is the lowest price target for WGS?
The lowest price target for WGS is $19.00, set by Mark Massaro at BTIG on 2024-04-30.
How many analysts cover WGS?
10 analysts have issued ratings for GeneDx Holdings Corp. in the past 12 months.
Is WGS a buy or sell right now?
Based on 10 analyst ratings, WGS has a consensus rating of Buy (2.00/5) with a +59.5% upside to the consensus target of $141.00.
What are the earnings estimates for WGS?
Analysts estimate WGS will report EPS of $0.79 for the period ending 2026-12-31, with revenue estimated at $550M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.